CME

Faculty: Maria Pabon, MD Faculty: Robert J. Mentz, MD, FHFSA, FACC In this brief podcast, Drs. Maria Pabon and Robert Mentz explore the evolving role of mineralocorticoid receptor antagonism in heart failure, with emphasis on patients who appear clinically stable yet remain at elevated biologic risk. They contrast steroidal and nonsteroidal MRAs, highlighting differences in receptor selectivity, c...

Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...

Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...

Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...

Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...

Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...

Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...

Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...

Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...

Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...

Host: Jay B. Wish, MD Expert-curated slides on the fundamentals of cardio–kidney–metabolic (CKM) syndrome, emphasizing alignment of clinical guidelines with patient-centered care and strategies for identifying and addressing patient-level barriers to treatment.

Faculty: Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD Faculty: Jennifer Sherr, MD, PhD If widespread use of continuous ketone monitoring (CKM) devices is to be safe and effective in reducing the occurrence of diabetic ketoacidosis (DKA), it is important to establish clear ketone thresholds which notify CKM users when action on their part is required. In preparation for availability and use in pra...

Faculty: David Staskin, MD Faculty: Matt T. Rosenberg, MD Faculty: Kennedy Koebbe, MSN, RN This audio-only podcast examines where contemporary approaches fall short when managing overactive bladder (OAB) in patients with complex clinical considerations, including women with persistent symptoms and men with coexisting benign prostatic hyperplasia (BPH). Faculty review clinical considerations suppor...

Faculty: Lewis S. Blevins, Jr, MD Faculty: James W. Suliburk, MD, FACS Cushing syndrome has seen exciting advances over the last couple of years, but how do they translate into improved patient care? Let’s dig into a couple of cases and discuss!

Faculty: Richard Lafayette, MD, FACP Faculty: Suzuki Yusuke, MD, PhD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g...

Faculty: Richard Lafayette, MD, FACP Faculty: Suzuki Yusuke, MD, PhD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g...

Faculty: Richard Lafayette, MD, FACP Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <...

Faculty: Richard Lafayette, MD, FACP Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <...

Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphasizing earlier esc...

Faculty: Dana Rizk, MD Faculty: Suzuki Yusuke, MD, PhD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0....

Faculty: Suzuki Yusuke, MD, PhD Faculty: Dana Rizk, MD IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0....

Faculty: Dana Rizk, MD Faculty: Hong Zhang IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and...

Faculty: Richard Lafayette, MD, FACP IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from <1.0 g/day to <0.3 g/day and emphas...

Faculty: Deepak Bhatt, MD, MPH, MBA, FACC, FAHA Faculty: Amir H. Hamrahian, MD 2025 delivered an expanded approval for Cushing syndrome for one agent, a complete response letter for another, and deeper insights on the prevalence of Cushing syndrome (or hypercortisolism) in people with difficult-to-control metabolic conditions. 2026 promises to be jam packed with further insights on Cushing syndrom...

Faculty: Jonathan Barratt, MD, PhD Professor Jonathan Barratt illustrates the integration of shared decision-making in the management of IgA nephropathy while interacting with a real patient with IgAN, highlighting how patient-centered conversations about proteinuria, GFR, and blood pressure can guide individualized treatment strategies. Emphasis is placed on explaining diagnostic findings such as...